- Home
- CAPL vs TNGX Comparison
CAPL vs TNGX Comparison
Compare CAPL & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPL
- TNGX
- Stock Information
- Founded
- CAPL 1992
- TNGX 2014
- Country
- CAPL United States
- TNGX United States
- Employees
- CAPL N/A
- TNGX N/A
- Industry
- CAPL Oil Refining/Marketing
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CAPL Energy
- TNGX Health Care
- Exchange
- CAPL Nasdaq
- TNGX Nasdaq
- Market Cap
- CAPL 793.6M
- TNGX 723.2M
- IPO Year
- CAPL 2012
- TNGX N/A
- Fundamental
- Price
- CAPL $21.34
- TNGX $7.62
- Analyst Decision
- CAPL
- TNGX Strong Buy
- Analyst Count
- CAPL 0
- TNGX 6
- Target Price
- CAPL N/A
- TNGX $10.00
- AVG Volume (30 Days)
- CAPL 24.6K
- TNGX 1.5M
- Earning Date
- CAPL 11-05-2025
- TNGX 11-05-2025
- Dividend Yield
- CAPL 9.84%
- TNGX N/A
- EPS Growth
- CAPL 100.77
- TNGX N/A
- EPS
- CAPL 1.13
- TNGX N/A
- Revenue
- CAPL $3,522,840,000.00
- TNGX $24,296,000.00
- Revenue This Year
- CAPL N/A
- TNGX $20.42
- Revenue Next Year
- CAPL N/A
- TNGX N/A
- P/E Ratio
- CAPL $18.95
- TNGX N/A
- Revenue Growth
- CAPL N/A
- TNGX N/A
- 52 Week Low
- CAPL $19.50
- TNGX $1.03
- 52 Week High
- CAPL $25.73
- TNGX $9.84
- Technical
- Relative Strength Index (RSI)
- CAPL 59.90
- TNGX 63.92
- Support Level
- CAPL $20.25
- TNGX $6.38
- Resistance Level
- CAPL $20.67
- TNGX $6.90
- Average True Range (ATR)
- CAPL 0.48
- TNGX 0.45
- MACD
- CAPL 0.07
- TNGX 0.05
- Stochastic Oscillator
- CAPL 94.40
- TNGX 80.12
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.